Clinical trials: Botox
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan
Glabellar Lines
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to…
- Trial name
- NCT05100199
- Testing
- OnabotulinumtoxinA X
- Where
- 18 sites in United States
- Volunteers
- 328 people
- Sponsor
- Allergan
Cervical Dystonia
Phase IV-Cervical Dystonia-INTEREST IN CD2
The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).
- Trial name
- INTEREST_INCD2 (NCT01753349)
- Testing
- Botulinum toxin type A
- Where
- 113 sites in United States, Algeria and 32 more
- Volunteers
- 1,050 people
- Sponsor
- Ipsen
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Overactive Bladder, Urinary Incontinence
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.
- Trial name
- NCT01767519
- Testing
- BOTOX®, solifenacin
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 356 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Urinary Incontinence, Urinary Bladder
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate…
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT02097121
- Testing
- BOTOX®
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 56 people
- Sponsor
- Allergan
Glabellar Rhytides
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
- Trial name
- PT-03c (NCT00752258)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 576 people
- Sponsor
- Mentor Worldwide, LLC
Skin Aging
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to test the hypothesis that the efficacy and safety of Meditoxin® are not inferior to Botox®'s in the treatment of glabellar lines.
- Trial name
- NCT01237977
- Testing
- Botulinum Toxin Type A(Meditoxin®), Botulinum Toxin Type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 314 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00888914
- Testing
- RT001, Vehicle Comparator
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Revance Therapeutics, Inc.
Moderate to Severe Glabellar Frown Lines
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
- Trial name
- NCT03806933
- Testing
- NT 201
- Where
- 9 sites in United States, Germany
- Volunteers
- 241 people
- Sponsor
- Merz Aesthetics GmbH
Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
ASIS for Botox in Chronic Migraine
Botox acts on nerve endings, yet there are no nerve endings inside the muscle, where they are typically injected. All nerves terminate on the fascia, where ASIS device can precisely deliver Botox by creating that subdermal…
- Trial name
- ASISinCM (NCT02074163)
- Testing
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- ASIS Corporation
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
Cervical Dystonia
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
This study will compare Xeomin®, a botulinum toxin medication, in shorter treatment intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) to determine if the response to treatment is comparable in both…
- Trial name
- NCT01486264
- Testing
- Xeomin®
- Where
- 43 sites in United States
- Volunteers
- 283 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Investigation of the clinical condition and safety in patients with cervical dystonia
- Trial name
- NCT02175693
- Where
- 2 sites in Japan
- Volunteers
- 1,647 people
- Sponsor
- Eisai Co., Ltd.
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
- Trial name
- NCT00651729
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 279 people
- Sponsor
- Allergan
Overactive Bladder
Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder
This First In Human study is aimed to evaluate the safety and initial efficacy of the Vibe delivery system in delivering Botox (TM) to the bladder wall in patients diagnosed with overactive bladder.
- Trial name
- NCT03874780
- Testing
- Vibe Delivery system
- Where
- 2 sites in Czechia, Portugal
- Volunteers
- 10 people
- Sponsor
- Vensica Therapeutics Ltd.
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968942
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
- Trial name
- NCT04081402
- Testing
- HU-014, Botox Inj
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.